Abstract 1799P
Background
Metastatic castration resistant prostate cancer (mCRPC) patients (pts) with HRR alterations (HRR+) benefit from PARPi. We aimed to elucidate the RW outcomes and impact of streamlined access to a biomarker driven tx approach.
Methods
In a multicentre prospective mPCa cohort study, cell free DNA next generation sequencing (cfDNA NGS) was performed using accredited assays (BC Cancer, Foundation Medicine, Alberta panel). Time to CRPC was compared between HRR+ and negative/unknown status (HRR0) using log rank test. In olaparib tx pts, ≥50% PSA decline, radiographic progression free survival (rPFS), serious adverse events (SAE), and overall survival (OS) were examined.
Results
Of 119 pts, 41 (35%) were HRR+ (23 BRCA2, 14 ATM, 5 CDK12, 3 CHEK2, 2 PPP2R2A, 1 BRCA1, 1 PALB2). Median age at diagnosis was 64 yrs, 45% had Gleason ≥ 8, and 13% were non-caucasian. HRR+ pts had a shorter time to CRPC than HRR0 pts (13.7 vs 31.3 months; HR: 2.2; p=0.001). 28 HRR+ pts (19 BRCA2, 8 ATM, 1 BRCA1) received olaparib, demonstrating a trend towards improved OS from mCRPC compared to HRR+ pts without PARPi (38.1 vs 17.4 mo, p=0.20). In 9 HRR+ pts without PARPi, 7 had androgen receptor pathway inhibitor (ARPi) tx and taxane, 1 had ARPi, and 1 had docetaxel. 50% of pts received olaparib after ≥2 systemic tx lines. A longer OS trend was observed in pts receiving 1st line mCRPC olaparib tx than pts receiving olaparib in later tx lines (17.2 vs 11.1 mo, p=0.07). OS from mCRPC was similar in HRR0 and olaparib tx HRR+ pts (37.4 vs 38.1 mo, p=0.70). In olaparib tx pts, median OS post initiation was 11.7 mo, rPFS was 5.4 mo, 36% had ≥50% PSA decline, and 29% had ≥30 days tx beyond PSA progression (PCWG3 criteria). SAE occurred in 39%; 4 pts required transfusion for anemia. Of 8 pts receiving additional systemic tx, 6 had taxane- and 2 had platinum-based chemotherapy.
Conclusions
In this study of heavily pre-treated mPCa pts, RW rPFS and OS on olaparib were reduced compared to clinical trials. Similar OS was seen in olaparib tx HRR+ and HRR0 pts, despite historically poorer prognosis in HRR+ pts. These results demonstrate that a biomarker driven tx approach and earlier access to PARPi may improve outcomes in HRR+ pts.
Clinical trial identification
Editorial acknowledgement
This was an ESCR performed with AstraZeneca funding support and collaboration.
Legal entity responsible for the study
The authors.
Funding
AstraZeneca.
Disclosure
S.M. Yip: Financial Interests, Personal, Advisory Board: Amgen, BMS, Novartis, Pfizer, Hoffman-La Roche, Ipsen; Financial Interests, Personal, Research Funding, Includes ad board/consultancy: Astellas, AstraZeneca, Merck, Bayer, Janssen; Financial Interests, Personal, Other, consultancy: Oncohelix. M. Kolinsky: Financial Interests, Personal, Invited Speaker: AstraZeneca, Bayer, Merck, Janssen; Financial Interests, Personal, Advisory Board: AstraZeneca, Astellas, BMS, Eisai, Ipsen, Merck, Janssen; Financial Interests, Institutional, Research Grant: Janssen, AstraZeneca. T. Tucker: Financial Interests, Institutional, Invited Speaker: AstraZeneca, Pfizer; Financial Interests, Institutional, Research Grant: Pfizer. P. Bose: Financial Interests, Personal, Ownership Interest, I am a co-founder and director in OncoHelix Inc: Oncohelix. T.A. Bismar: Financial Interests, Personal, Other, advisory role: xpherabio; Financial Interests, Institutional, Funding, funding support for fellow: AstraZeneca. D.Y.C. Heng: Financial Interests, Personal, Advisory Board: Pfizer, Merck, BMS, Ipsen, Novartis, AstraZeneca, Roche; Financial Interests, Personal, Steering Committee Member: Exilexis; Financial Interests, Institutional, Local PI: BMS, Pfizer, Ipsen. S. North: Financial Interests, Personal, Advisory Board, honoraria: Astellas, BMS, Janssen, Merck, Roche, Sanofi, Bayer, AstraZeneca; Financial Interests, Institutional, Local PI, per case funding: Sanofi, AstraZeneca, Ipsen, Astellas. N. Alimohamed: Financial Interests, Personal, Advisory Board: Bayer, Seagen, EMD Serono, BMS, Gilead. N.S. Basappa: Financial Interests, Personal, Advisory Board: Ipsen, Eisai, Pfizer, AstraZeneca, Janssen Inc, EMD Serono, Astellas, Bayer, BMS, Seagen, Takeda; Financial Interests, Institutional, Research Grant, Research Grant: Ipsen; Other, Other, Travel grant/support: Ipsen; Other, Other, Travel Grant/support: Eisai. K.N.N. Chi: Financial Interests, Personal, Invited Speaker: Astellas, AstraZeneca, Janssen, Point Biopharma, Roche; Financial Interests, Personal, Advisory Board: AstraZeneca, AstraZeneca, Janssen, Merck, Novartis, Pfizer, Point Biopharma, Roche, BMS; Financial Interests, Institutional, Steering Committee Member: AstraZeneca, Janssen, Novartis, Roche; Financial Interests, Institutional, Trial Chair: AstraZeneca, Arvinas, Janssen, Novartis; Financial Interests, Institutional, Local PI: Arvinas. S.E. El Hallani: Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Full or part-time Employment: Alberta Precision Labs; Financial Interests, Institutional, Research Grant: AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
1229P - Selective phenotypic and genotypic evaluation of circulating glial cells for improved diagnosis of glial malignancies
Presenter: Sewanti Limaye
Session: Poster session 14
1230P - hPG80 (circulating progastrin) is a new blood-based biomarker for diagnosis of early-stage non-small cell lung cancers
Presenter: Paul Hofman
Session: Poster session 14
1231P - Machine learning prediction of the case-fatality of COVID-19 and risk factors for adverse outcomes in patients with non-small cell lung cancer
Presenter: Yeji Jung
Session: Poster session 14
1232P - Analytic analysis of PanSeer7, a targeted bisulfite sequencing assay for blood-based multi-cancer detection for cancer early detection and tissue-of-origin identification
Presenter: Xinrong Yang
Session: Poster session 14
1233P - Accurate prediction of gastrointestinal cancer tissue of origin using comprehensive plasma cell-free DNA fragmentomics features
Presenter: Xinrong Yang
Session: Poster session 14
1234P - HistoMate: Automated preprocessing software for digital histopathology image to enhance deep learning
Presenter: Jinok Lee
Session: Poster session 14
1235P - Enrichment of rare cancers in pragmatic precision cancer medicine trial: Experience from IMPRESS-Norway
Presenter: Aaslaug Helland
Session: Poster session 14
1236P - Feasibility of online symptom monitoring to detect lung cancer relapse in Poland
Presenter: Ewa Pawlowska
Session: Poster session 14
1237P - Design and validation of a custom next-generation sequencing panel in melanoma, glioma and gastrointestinal stromal tumor
Presenter: Xiaoyan Zhou
Session: Poster session 14
1238P - Detecting driver mutations by AmoyDx 11-gene PCR with high concordance with next-generation sequencing in Chinese non-small cell lung cancer patients
Presenter: Dongmei Lin
Session: Poster session 14